These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 26267728

  • 1. Erythema of Rosacea: Validation of Patient's Self-Assessment Grading Scale.
    Tan J, Leoni M.
    J Drugs Dermatol; 2015 Aug; 14(8):841-4. PubMed ID: 26267728
    [Abstract] [Full Text] [Related]

  • 2. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
    Layton AM, Schaller M, Homey B, Hofmann MA, Bewley AP, Lehmann P, Nohlgård C, Sarwer DB, Kerrouche N, Ma YM.
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
    Fowler J, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, Steinhoff M, Rudisill D, Leoni M.
    J Drugs Dermatol; 2013 Jun 01; 12(6):650-6. PubMed ID: 23839181
    [Abstract] [Full Text] [Related]

  • 4. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
    Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M, Brimonidine Phase II Study Group.
    Br J Dermatol; 2012 Mar 01; 166(3):633-41. PubMed ID: 22050040
    [Abstract] [Full Text] [Related]

  • 5. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea.
    Jackson JM, Fowler J, Moore A, Jarratt M, Jones T, Meadows K, Steinhoff M, Rudisill D, Leoni M, Brimonidine Phase III Study Group.
    J Drugs Dermatol; 2014 Jun 01; 13(6):699-704. PubMed ID: 24918560
    [Abstract] [Full Text] [Related]

  • 6. Reliability of Clinician Erythema Assessment grading scale.
    Tan J, Liu H, Leyden JJ, Leoni MJ.
    J Am Acad Dermatol; 2014 Oct 01; 71(4):760-3. PubMed ID: 24999270
    [Abstract] [Full Text] [Related]

  • 7. Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema.
    Fowler J, Tan J, Jackson JM, Meadows K, Jones T, Jarratt M, Leoni M, Brimonidine Phase III Study Group.
    J Eur Acad Dermatol Venereol; 2015 Mar 01; 29(3):474-81. PubMed ID: 25074756
    [Abstract] [Full Text] [Related]

  • 8. Rosacea or photodamaged skin? Use of brimonidine gel in differentiating erythema in the two conditions.
    Oon HH, Lim ZV.
    Australas J Dermatol; 2017 Feb 01; 58(1):63-64. PubMed ID: 26763464
    [Abstract] [Full Text] [Related]

  • 9. Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options.
    Steinhoff M, Schmelz M, Schauber J.
    Acta Derm Venereol; 2016 Jun 15; 96(5):579-86. PubMed ID: 26714888
    [Abstract] [Full Text] [Related]

  • 10. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea.
    Benkali K, Leoni M, Rony F, Bouer R, Fernando A, Graeber M, Wagner N.
    Br J Dermatol; 2014 Jul 15; 171(1):162-9. PubMed ID: 24506775
    [Abstract] [Full Text] [Related]

  • 11. Topical brimonidine tartrate 0·33% gel effectively reduces the post-treatment erythema of daylight-activated photodynamic therapy.
    Gerber PA.
    Br J Dermatol; 2016 Jun 15; 174(6):1422-3. PubMed ID: 26727630
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
    Draelos ZD, Gold MH, Weiss RA, Baumann L, Grekin SK, Robinson DM, Kempers SE, Alvandi N, Weng E, Berk DR, Ahluwalia G.
    J Am Acad Dermatol; 2018 Jun 15; 78(6):1156-1163. PubMed ID: 29409914
    [Abstract] [Full Text] [Related]

  • 13. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
    Lowe E, Lim S.
    J Drugs Dermatol; 2016 Jun 01; 15(6):763-5. PubMed ID: 27272086
    [Abstract] [Full Text] [Related]

  • 14. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
    Cookson H, McFadden J, White J, White IR.
    Contact Dermatitis; 2015 Dec 01; 73(6):366-7. PubMed ID: 26768997
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component.
    Micali G, Dall'Oglio F, Verzì AE, Luppino I, Bhatt K, Lacarrubba F.
    Lasers Med Sci; 2018 Aug 01; 33(6):1397-1400. PubMed ID: 28889348
    [Abstract] [Full Text] [Related]

  • 16. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
    Tong LX, Moore AY.
    Expert Rev Clin Pharmacol; 2014 Sep 01; 7(5):567-77. PubMed ID: 25091290
    [Abstract] [Full Text] [Related]

  • 17. Brimonidine for erythema caused by rosacea.
    Drug Ther Bull; 2014 Dec 01; 52(12):138-40. PubMed ID: 25505014
    [Abstract] [Full Text] [Related]

  • 18. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
    Kircik LH, DuBois J, Draelos ZD, Werschler P, Grande K, Cook-Bolden FE, Weng E, Berk DR, Ahluwalia G.
    J Drugs Dermatol; 2018 Jan 01; 17(1):97-105. PubMed ID: 29320594
    [Abstract] [Full Text] [Related]

  • 19. [Erythema of rosacea: a new and effective treatment].
    Hougeir FG.
    Ann Dermatol Venereol; 2014 Sep 01; 141 Suppl 2():S169-74. PubMed ID: 25151933
    [Abstract] [Full Text] [Related]

  • 20. Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea.
    Kuang AW, DuBois J, Attar M, Ahluwalia G.
    J Drugs Dermatol; 2018 Feb 01; 17(2):213-220. PubMed ID: 29462230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.